Celldex Therapeutics Inc
F:TCE2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Celldex Therapeutics Inc
F:TCE2
|
US |
|
S
|
Salesforce Inc
XETRA:FOO
|
US |
|
Intel Corp
SIX:INTC
|
US |
|
S
|
State Bank of India
F:SID
|
IN |
Shareholder Yield
Current shareholder yield for 
TCE2 is
hidden
.
Peers Comparison
Shareholder Yield
Buybacks
Buyback Yield measures how much a company reduces its outstanding shares through repurchases, expressed as a percentage.
This metric directly reflects the company’s efforts to return value to shareholders. By reducing the number of shares, buybacks can increase earnings per share and potentially boost the stock's price.
Peers Comparison
Buybacks
Debt Paydown
Debt Paydown Yield measures the amount of debt a company repays within a specific period, shown as a percentage of its market capitalization.
This metric indicates how the company is using its capital to decrease financial liabilities, which can strengthen its financial health and potentially enhance shareholder value.
Peers Comparison
Debt Paydown
Price Appreciation
TCE2 Price
Celldex Therapeutics Inc
| Average Annual Return | 7.1% |
| Standard Deviation of Annual Returns | 37.02% |
| Max Drawdown | -73% |
| Market Capitalization | 2.6B EUR |
| Shares Outstanding | 65 910 000 |
| Percentage of Shares Shorted |
N/A
|
TCE2 Return Decomposition
Main factors of price return
Stock Splits
TCE2's latest stock split occurred on Feb 11, 2019
The company executed a 1-for-15 stock split, meaning that for every 15 shares held, investors received 1 new share.
Before the split, TCE2 traded at 0.488 per share. Afterward, the share price was about 4.19.
The adjusted shares began trading on Feb 11, 2019. This was the only stock split in TCE2's history.
